News About: R&D
Multiple myeloma therapy, ‘Kyprolis’ conducted Phase 3 clinical trials on Koreans
The new multiple myeloma therapy, ‘Kyprolis(carfilzomib, Amgen),’ will start a Phase 3 clinical trial adding 16 Korean subjects.
It has attracted interests of the industry since it is a newly-approved clinical trial ...
Next-generation dementia therapy’s Phase 3 clinical trials starts in Korea
The next generation dementia therapy, which was expected to generate approximately KRW 1 trillion prescriptions in the global market, was approved to conduct Phase 3 clinical trials in Korea.
The therapy is ‘RVT-101’...
Celltrion starts global Phase 3 clinical trials on Remsima’s SC typeIn order to secure competitiveness in the TNF-α inhibitor(autoimmune disease therapy) market, Celltrion will start the global Phase 3 clinical trial of the Remsima’s SC type(sub...
|
Arguments about Sanofi’s Menactra clinical trials for childrenSince Sanofi-Pasteur’s ‘Menactra,’ a competing product of the GSK’s top meningococcal meningitis vaccine in Korea, ‘Menveo,’ has been conducted for clinical trials to extend ind...
|
Korea Drug Development Fund to conclude joint anticancer R&D agreement
The Korea Drug Development Fund(Head Sang-Un Joo, hereinafter referring to KDDF) will start the ‘BigPharma Joint R&D Program’ in regards of anticancer development researches.
On the 8th, the KDDF announced it conclu...
Osong & Daegu Medical Innovation Foundations’ cooperation with largest European BioCluster
On the 5th, Osong Medical Innovation Foundation(Chief Director Kyung Sun) and Daegu Gyeongbuk Medical Innovation Foundation(Chief Director Jae-tae Lee) announced conclusion of the Strategic Exploratory Agreement(SEA) ...
Extended tax deductions for new drug R&Ds
In order to foster new industries, the government decided to apply tax deduction even for expenses of Phase 3 clinical trials that are conducted in Korea.
Moreover, it also decided to raise the ‘New Industry Fosterin...
7 pharmaceutical companies to spend more than KRW 50 billion into R&D
Among listed pharmaceutical companies, there were 7 companies which invested more than KRW 50 billion into R&D expenses last year, including Hanmi Pharm and Green Cross.
Moreover, although many companies seem to acti...
Treatment spent the most R&D expenses, ‘tumor treatment’
A treatment spent the most R&D expenses by pharmaceutical companies was known to be tumor treatments.
The Korea Health Industry Development Institute recently unveiled the information through the ‘2014 Pharmaceutical...
Drug Research Association proposes ‘Expansion Of Target Technology For Tax Deduction On Pharmaceutical R&D Expenses’
The Korea Drug Research Association(Chairperson Dong-yeon Kim) submitted the ‘Opinions For The Review Of Technology Targeting Tax Deduction On New Growth Engine and Source Technology Research and Development’(Recommen...
